Fate can be altered

Discovering and developing first-in-class small molecule drugs for improved treatment of diseases with significant clinical need.

More info More info


We aim to become globally recognized for developing breakthrough therapies to treat incurable diseases. Through intelligent identification and validation of protein and mRNA targets that drive disease progression and modulating their activity with small molecules, we strive to change the fate of patients by stopping the progression and reversing the effects of diseases with unmet medical need.

More info More info


Molecure’s exceptional in-house medicinal chemistry, biology and discovery capabilities allied to novel target biology gained from leading universities worldwide has enabled us to create a broad pipeline of drug candidates targeting unique and unexplored protein targets, as well as a cutting-edge small molecule mRNA targeting discovery platform.

Discover our pipeline Discover our pipeline


On the 28th March 2022, OncoArendi changed its name to Molecure

Molecure has confirmed the in vitro activity of another molecule binding to a new mRNA target within the mRNA discovery platform

12 June 2024

Molecure receives approval to initiate a Phase II clinical trial (KITE) for OATD-01 for the treatment of pulmonary sarcoidosis in selected countries of the European Union and Norway

21 May 2024

Molecure has published its financial report for the first quarter of 2024. The company is progressing, as anticipated, the next steps in the development of its clinical and pre-clinical programmes

17 May 2024

Join us

People are the foundation of Molecure’s success. Our scientists are the creators of the best ideas for the multiple new small molecule medicines that are invented in the laboratories. The Molecure team works together to discover the therapies needed to improve the treatment of previously incurable diseases.
It is this unified goal that guides us every day. We are inspired by science, we discover and create. For us, work is a passion.

More info More info